BMA In Focus




Pakistan Cement Sector

Cement dispatches remain unappealing; decline by 7% YoY in Feb'23

Monday, March 6, 2023


All Pakistan Cement Manufacturers Association (APCMA) released monthly cement numbers where the total cement dispatches for Feb'23 were reported at 4.04Mn tons as against 4.35Mn tons last year, registering a decline of 7% YoY. Moreover, in 8MFY23, total dispatches reached 29.81Mn tons as compared to 35.76Mn tons in the SPLY, depicting a drop of 17% YoY.

- Local dispatches plunged by 9% YoY in Feb'23 to clock-in at 3.59Mn tons and we expect the trend to continue in the remaining months of the ongoing fiscal year on the back of reduced govt. spending and limited purchasing power of the general public. However, recovery in local cement demand from FY24 can be expected as the work on damaged infrastructure and rehabilitation of masses picks up momentum which will also by aided by the successful resumption of the IMF program and resultantly multilateral flows. On the flip side, retail cement prices are assumed to hold ground on the back of inflationary pressures with the cement manufacturers not ready to compromise on gross margins.
- Talking about segments, North based cement mills sold 2.95Mn tons in the domestic markets, down by 8% YoY while South based mills sold 0.64Mn tons that were 12% lower YoY. Exports in Feb'23 increased by 11% YoY to 0.45Mn tons from 0.41Mn tons in Feb'22.
- Given the weak sales trend amid a high inflation environment, we advise positions in low leverage, relatively insulated to energy tariff hikes and less reactive companies. Our top picks are LUCK, FCCL & KOHC.



Source: APCMA, BMA Research

Cement prices trending up



Source: Bloomberg, PBS, BMA Research

Cement Dispatches

| Mn tons | Feb-23 | Feb-22 | YoY | Jan-23 | MoM | 8MFY23 | 8MFY22 | YoY |
|--------------|--------|--------|------|--------|------|--------|--------|------|
| North | 3.01 | 3.26 | -7% | 2.89 | 4% | 23.01 | 26.69 | -14% |
| Local | 2.95 | 3.22 | -8% | 2.86 | 3% | 22.33 | 26.09 | -14% |
| Export | 0.06 | 0.04 | 58% | 0.04 | 84% | 0.68 | 0.60 | 13% |
| South | 1.03 | 1.09 | -6% | 1.11 | -8% | 6.80 | 9.08 | -25% |
| Local | 0.64 | 0.73 | -12% | 0.73 | -12% | 4.88 | 5.33 | -8% |
| Export | 0.39 | 0.36 | 6% | 0.38 | 1% | 1.92 | 3.75 | -49% |
| Total Local | 3.59 | 3.94 | -9% | 3.59 | 0% | 27.21 | 31.42 | -13% |
| Total Export | 0.45 | 0.41 | 11% | 0.42 | 8% | 2.60 | 4.35 | -40% |
| Total | 4.04 | 4.35 | -7% | 4.01 | 1% | 29.81 | 35.76 | -17% |

Source: APCMA, BMA Research

Fahad Hussain Khan

Senior Research Analyst Tel: 111-262-111 Ext. 2062

E-mail: fahad.hussain@bmacapital.com

BMA Capital Management Ltd.



Disclaimer

This research report is for information purposes only and does not constitute nor is it intended as an offer or solicitation for the purchase or sale of securities or other financial instruments. Neither the information contained in this research report nor any future information made available with the subject matter contained herein will form the basis of any contract. Information and opinions contained herein have been compiled or arrived at by BMA Capital Management Limited from publicly available information and sources that BMA Capital Management Limited believed to be reliable. Whilst every care has been taken in preparing this research report, no research analyst, director, officer, employee, agent or adviser of any member of BMA Capital Management Limited gives or makes any representation, warranty or undertaking, whether express or implied, and accepts no responsibility or liability as to the reliability, accuracy or completeness of the information set out in this research report. Any responsibility or liability for any information contained herein is expressly disclaimed. All information contained herein is subject to change at any time without notice. No member of BMA Capital Management Limited has an obligation to update, modify or amend this research report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. Furthermore, past performance is not indicative of future results.

The investments and strategies discussed herein may not be suitable for all investors or any particular class of investor. Investors should make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives when investing. Investors should consult their independent advisors if they have any doubts as to the applicability to their business or investment objectives of the information and the strategies discussed herein. This research report is being furnished to certain persons as permitted by applicable law, and accordingly may not be reproduced or circulated to any other person without the prior written consent of a member of BMA Capital Management Limited. This research report may not be relied upon by any retail customers or person to whom this research report may not be provided by law. Unauthorized use or disclosure of this research report is strictly prohibited. Members of BMA Capital Management and/or their respective principals, directors, officers and employees may own, have positions or effect transactions in the securities or financial instruments referred herein or in the investments of any issuers discussed herein, may engage in securities transactions in a manner inconsistent with the research contained in this research report and with respect to securities or financial instruments covered by this research report, may sell to or buy from customers on a principal basis and may serve or act as director, placement agent, advisor or lender, or make a market in, or may have been a manager or a co-manager of the most recent public offering in respect of any investments or issuers of such securities or financial instruments referenced in this research report or may perform any other investment banking or other services for, or solicit investment banking or other business from any company mentioned in this research report. Investing in Pakistan involves a high degree of risk and many persons, physic

BMA Capital Management Limited and / or any of its affiliates, which operate outside Pakistan, do and seek to do business with the company(s) covered in this research document. Investors should consider this research report as only a single factor in making their investment decision. BMA Research Policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer/company prior to the publication of a research report containing such rating, recommendation or investment thesis.

Stock Rating

Investors should carefully read the definitions of all rating used within every research reports. In addition, research reports carry an analyst's independent view and investors should ensure careful reading of the entire research reports and not infer its contents from the rating ascribed by the analyst. Ratings should not be used or relied upon as investment advice. An investor's decision to buy, hold or sell a stock should depend on said individual's circumstances and other considerations. BMA Capital Limited uses a three tier rating system: i) Buy, ii) Neutral and iii) Underperform (new rating system effective Jan 1'18) with our rating being based on total stock returns versus BMA's index target return for the year. A table presenting BMA's rating definitions is given below:

| Buy | >15% expected total return | | | |
|---|-------------------------------|--|--|--|
| Hold | 10%-15% expected total return | | | |
| Underperform | <10% expected total return | | | |
| *Total stock return = capital gain + dividend yield | | | | |

Old rating system

| Overweight | Total sector return > expected market return |
|--------------|--|
| Marketweight | Expected market return |
| Underweight | Total stock return < expected market return |

Valuation Methodology

To arrive at our period end target prices, BMA Capital uses different valuation methodologies including

- Discounted cash flow (DCF, DDM)
- Relative Valuation (P/E, P/B, P/S etc.)
- Equity & Asset return based methodologies (EVA, Residual Income etc.)

Monday, March 6, 2023